3 results
Approved WMORecruiting
To test the hypothesis that LY3314814, administered orally at doses of 20 and 50 mg daily for 78 weeks, will slow the decline of AD ascompared with placebo in patients with mild AD dementia.
Approved WMORecruiting
The main objective is the %TBWL 5 years after surgery. Secondary objectives include Percentage Excess Weight Loss (%EWL); decrease of comorbidities such as diabetes mellitus (DM), hypertension, and hypercholesterolemia; improvement of quality of…
Approved WMORecruiting
To determine the median progression-free survival (PFS) and R0/1 secondary resection rate upon induction systemic treatment in colorectal cancer patients with initially unresectable liver-only metastases, stratified by RAS and BRAF tumor mutation…